Individuals who have inherited a pathogenic variant have a dramatically higher risk of developing cancer, and many of these cancers can be difficult to detect and treat. It is extremely helpful to identify these high-risk individuals so that additional screening, surveillance, and interventions can be started. These efforts can result in risk reduction and early diagnosis, which increases the chances of prevention, successful treatment, and survival.
Early Detection is the Key
Knowledge of an increased genetic risk of any cancer enables you to work with your healthcare provider to create a personalized plan designed to prevent or detect cancer at an earlier and more treatable stage. If cancers are found early, there are more treatment options and a better chance of survival. People whose cancer is detected at an early stage have a 95 percent or higher survival rate in the first five years.
How Cancer Starts, Spreads?
Cancer is caused by damage to the DNA in your cells. These changes are called “gene mutations.” Gene mutations are inherited from parents or can build up in cells in your body over time. Cells with too many mutations may stop working normally, grow out of control and become cancerous. Cancers are found because they are causing symptoms and tend to be more advanced. In contrast, Early detection of any cancer is important as it is associated with an increased number of available prevention, and treatment options.
The Science Behind the Test
Men and women can pass an inherited gene mutation to their sons or daughters through their sperm or eggs. When a person with a gene mutation has children, each child has a 50 percent chance of inheriting the same mutation. Breast & Ovarian cancer can also be inherited in the same way. Our Genetics experts look carefully at a family’s medical history for signs of hereditary cancer. You can assist them by gathering medical information from relatives on both sides of your family. Combined with proactive DNA testing your chance to win against cancer is more than 95%.
Who Needs this DNA Test?
Early Detection is Key, Cancer is the most diagnosed disease all over the world, affecting one in every 3 persons. The goal of This Test is early cancer detection. If the cancer is found early, there are more treatment options and a better chance of survival. People whose cancer is detected at an early stage have a 95 percent or higher survival rate in the first five years. Everyone deserves this Testing option.
What We Test?
AIP ALK APC ATM AXIN2 BAP1 BARD1 BLM BMPR1A BRCA1 BRCA2 BRIP1 CASR CDC73 CDH1 CDK4 CDKN1B CDKN1C CDKN2A CEBPA CHEK2 CTNNA1 DICER1 DIS3L2 EGFR EPCAM FH FLCN GATA2 GPC3 GREM1 HOXB13 HRAS KIT MAX MEN1 MET MITF MLH1 MSH2 MSH3 MSH6 MUTYH NBN NF1 NF2 NTHL1 PALB2 PDGFRA PHOX2B PMS2 POLD1 POLE POT1 PRKAR1A PTCH1 PTEN RAD50 RAD51C RAD51D RB1 RECQL4 RET RUNX1 SDHA SDHAF2 SDHB SDHC SDHD SMAD4 SMARCA4 SMARCB1 SMARCE1 STK11 SUFU TERC TERT TMEM127 TP53 TSC1 TSC2 VHL WRN WT1
This Multi-Cancer DNA Test analyzes 84 genes associated with hereditary cancers across major organ systems, including:
Breast and gynecologic (breast, ovarian, uterine)
gastrointestinal (colorectal, gastric, pancreatic)
endocrine (thyroid, paraganglioma/pheochromocytoma, parathyroid, pituitary)
genitourinary (renal/urinary tract, prostate)
skin (melanoma, basal cell carcinoma)
brain/nervous system
sarcoma
hematologic (myelodysplastic syndrome/leukemia)
Comprehensive Cancer Test Analyses more than 20 cancer.
breast, ovarian, uterine, colorectal, gastric, pancreatic, thyroid, pituitary, parathyroid, paraganglioma/pheochromocytoma, renal/urinary tract, prostate, melanoma, basal cell carcinoma, brain/nervous system, sarcoma, myelodysplastic syndrome/leukemia.
Individuals who have inherited a pathogenic variant help to detect and treat. It is extremely helpful to identify these high-risk individuals so that additional screening, surveillance, and interventions can be started. These efforts can result in risk reduction and early diagnosis, which increases the chances of successful treatment and survival.
Our Lab is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS). Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequences on either side of the coding exons in the transcript listed below, depending on the specific gene or test. In addition, the analysis covers select non-coding variants. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed in the report. Contact client services with any questions. Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications.
How it Works?
The process is as simple as ordering a kit from our lab. When it arrives after 3 business days, you will collect a saliva sample using the saliva collection Tube, provided in the kit. Then, just send it back in the prepaid mailer, and we will send it to our CAP, CLIA-accredited Lab in the USA. Your results will be ready in 2-4 weeks. (Average time is 3 weeks).
